Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00677807 · ClinicalTrials.gov registry record · Phase 3
Safety, Tolerability and Efficacy of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)
A Phase 3 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 415
- Enrollment target
NCT00677807 is a Phase 3 study that has completed, run by Novartis. The registered enrollment target is 415 participants.
The verdict
NCT00677807, a Phase 3 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 415 participants
- Enrollment target
Study Summary
This study evaluated the 1 year safety, tolerability and efficacy of indacaterol against placebo in the treatment of Chronic Obstructive Pulmonary Disease (COPD) patients
Interventions
- DRUG Placebo
- DRUG Indacaterol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 415 participants |
| Start Date | 2008-05 |
| Est. Completion | 2009-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00677807
The ClinicalTrials.gov registry entry for NCT00677807 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 415 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00677807 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00677807 about?
NCT00677807 is a clinical study titled "Safety, Tolerability and Efficacy of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)". This study evaluated the 1 year safety, tolerability and efficacy of indacaterol against placebo in the treatment of Chronic Obstructive Pulmonary Disease (COPD) patients
What is the current status of trial NCT00677807?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 415 participants. The study started on 2008-05. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00677807?
The interventions under investigation include: Placebo (DRUG), Indacaterol (DRUG).
Who is sponsoring clinical trial NCT00677807?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.